A citation-based method for searching scientific literature

Bruce J Giantonio, Paul J Catalano, Neal J Meropol, Peter J O'Dwyer, Edith P Mitchell, Steven R Alberts, Michael A Schwartz, Al B Benson. J Clin Oncol 2007
Times Cited: 1648







List of co-cited articles
818 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004
41

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013
720
40

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannova, Gyorgy Bodoky, Rocio Garcia-Carbonero, Tudor-Eliade Ciuleanu, David C Portnoy, Eric Van Cutsem, Axel Grothey,[...]. Lancet Oncol 2015
464
33

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera,[...]. J Clin Oncol 2008
33

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Eric Van Cutsem, Josep Tabernero, Radek Lakomy, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A van Hazel, Vladimir Moiseyenko, David Ferry,[...]. J Clin Oncol 2012
801
32

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone,[...]. Lancet 2013
27

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
E Van Cutsem, A Cervantes, R Adam, A Sobrero, J H Van Krieken, D Aderka, E Aranda Aguilar, A Bardelli, A Benson, G Bodoky,[...]. Ann Oncol 2016
23

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
21

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J A Punt,[...]. J Clin Oncol 2010
664
18

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni,[...]. Lancet Oncol 2015
471
18

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi,[...]. N Engl J Med 2014
570
18

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky,[...]. N Engl J Med 2009
17

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
342
17

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
David Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Dong Bok Shin, Derek Jonker, Stuart Osborne, Niko Andre, Daniel Waterkamp,[...]. Lancet Oncol 2013
360
16

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Michael J Overman, Ray McDermott, Joseph L Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A Morse, Jayesh Desai, Andrew Hill, Michael Axelson, Rebecca A Moss,[...]. Lancet Oncol 2017
16

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
16

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A Abubakr, Manfred P Lutz, M Eugenia Vega-Villegas, Cathy Eng, Ernst U Steinhauer, Jana Prausova,[...]. J Clin Oncol 2008
683
16

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt,[...]. Lancet Oncol 2014
14

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu,[...]. N Engl J Med 2015
586
13

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype,[...]. N Engl J Med 2004
13

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
13

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Niall C Tebbutt, Kate Wilson, Val J Gebski, Michelle M Cummins, Diana Zannino, Guy A van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P Ackland,[...]. J Clin Oncol 2010
293
12

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem,[...]. J Clin Oncol 2010
12

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson,[...]. J Clin Oncol 2007
12

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Rafael G Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky,[...]. J Clin Oncol 2008
12

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, Chris J O'Callaghan, Dongsheng Tu, Niall C Tebbutt, R John Simes, Haji Chalchal, Jeremy D Shapiro, Sonia Robitaille,[...]. N Engl J Med 2008
12

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, M Schirripa, S Cupini, C Barbara, V Safina,[...]. Ann Oncol 2015
101
12

Cetuximab for the treatment of colorectal cancer.
Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, John R Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott R Berry, Marianne Krahn, Timothy Price, R John Simes,[...]. N Engl J Med 2007
11

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Christophe Tournigand, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard Ganem,[...]. J Clin Oncol 2004
11

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
J Y Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, Y Humblet, G Bodoky, D Cunningham, J Jassem,[...]. Ann Oncol 2014
293
11

The consensus molecular subtypes of colorectal cancer.
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino,[...]. Nat Med 2015
11


Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A Meyerhardt, Deborah Schrag, Claire Greene, Bert H O'Neil, James Norman Atkins,[...]. JAMA 2017
361
11

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar,[...]. J Clin Oncol 2011
10

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis, K Yamazaki, R-H Xu, T W Kim, F Ismail, I B Tan, K-H Yeh,[...]. Ann Oncol 2018
198
10

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini,[...]. J Clin Oncol 2007
755
10

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Matthew T Seymour, Sarah R Brown, Gary Middleton, Timothy Maughan, Susan Richman, Stephen Gwyther, Catherine Lowe, Jennifer F Seligmann, Jonathan Wadsley, Nick Maisey,[...]. Lancet Oncol 2013
258
10

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Timothy J Price, Marc Peeters, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Atilli Satya Suresh, Anne Thomas, Sergei Tjulandin, Kathy Zhang,[...]. Lancet Oncol 2014
253
10

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
10

The biology of VEGF and its receptors.
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter. Nat Med 2003
10

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli,[...]. Lancet Oncol 2016
425
10

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004
9

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Fairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, Neal J Meropol, William F Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland. J Clin Oncol 2003
9

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Fairooz F Kabbinavar, Joseph Schulz, Michael McCleod, Taral Patel, John T Hamm, J Randolph Hecht, Robert Mass, Brent Perrou, Betty Nelson, William F Novotny. J Clin Oncol 2005
691
9

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
K Yamazaki, M Nagase, H Tamagawa, S Ueda, T Tamura, K Murata, T Eguchi Nakajima, E Baba, M Tsuda, T Moriwaki,[...]. Ann Oncol 2016
109
8

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
D Arnold, B Lueza, J-Y Douillard, M Peeters, H-J Lenz, A Venook, V Heinemann, E Van Cutsem, J-P Pignon, J Tabernero,[...]. Ann Oncol 2017
371
8

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Eric Van Cutsem, Heinz-Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, Ivan Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J Han van Krieken,[...]. J Clin Oncol 2015
463
8

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Sandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli. Cancer Discov 2014
272
8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
8



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.